# Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes

> **NCT00518882** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 467 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** liraglutide
- **DRUG:** exenatide

## Key facts

- **NCT ID:** NCT00518882
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2008-04
- **Final completion:** 2009-04
- **Target enrollment:** 467 (ACTUAL)
- **Last updated:** 2017-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00518882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00518882, "Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00518882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*